MX2023000165A - Productos de combinacion de dosis fijas de tres antibioticos, regimen de dosificacion, metodos y kits para tratar infecciones micobacterianas pulmonares no tuberculosas. - Google Patents
Productos de combinacion de dosis fijas de tres antibioticos, regimen de dosificacion, metodos y kits para tratar infecciones micobacterianas pulmonares no tuberculosas.Info
- Publication number
- MX2023000165A MX2023000165A MX2023000165A MX2023000165A MX2023000165A MX 2023000165 A MX2023000165 A MX 2023000165A MX 2023000165 A MX2023000165 A MX 2023000165A MX 2023000165 A MX2023000165 A MX 2023000165A MX 2023000165 A MX2023000165 A MX 2023000165A
- Authority
- MX
- Mexico
- Prior art keywords
- fixed
- dose
- dose combination
- treating pulmonary
- mac
- Prior art date
Links
- 229940000425 combination drug Drugs 0.000 title abstract 5
- 230000002685 pulmonary effect Effects 0.000 title abstract 3
- 206010062207 Mycobacterial infection Diseases 0.000 title 1
- 230000003115 biocidal effect Effects 0.000 title 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 title 1
- 201000008827 tuberculosis Diseases 0.000 title 1
- 229940126534 drug product Drugs 0.000 abstract 4
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 4
- 208000033126 Colobomatous microphthalmia Diseases 0.000 abstract 3
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 abstract 3
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 abstract 3
- 229960002626 clarithromycin Drugs 0.000 abstract 3
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 abstract 3
- 229960004287 clofazimine Drugs 0.000 abstract 3
- 208000034367 isolated with coloboma microphthalmia Diseases 0.000 abstract 3
- 229960000885 rifabutin Drugs 0.000 abstract 3
- 208000032376 Lung infection Diseases 0.000 abstract 2
- 208000022155 mycobacterium avium complex disease Diseases 0.000 abstract 2
- 241000186367 Mycobacterium avium Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un producto farmacológico de combinación de dosis fijas formulado para suministro oral comprende una dosis fija de 158.3 mg de claritromicina, una dosis fija de 13.3 mg de clofazimina y una dosis fija de 40.0 mg de rifabutina. El producto farmacológico de combinación de dosis fijas está diseñado suficientemente para ser usado en el tratamiento de la enfermedad por el complejo Mycobacterium avium (CMA) pulmonar en un sujeto que lo necesita. Un método para tratar la enfermedad por el CMA en un ser humano que tiene una infección del pulmón por el CMA que comprende administrar por vía oral, dos veces al día, aproximadamente 475 mg de claritromicina, aproximadamente 40 mg de clofazimina y aproximadamente 120 mg de rifabutina. Un kit para tratar la enfermedad por el CMA pulmonar en un individuo que tiene una infección del pulmón por el CMA comprende un suministro de productos farmacológicos de combinación de dosis fijas, en donde cada uno de los productos farmacológicos de combinación de dosis fijas comprende una dosis fija de 158.3 mg de claritromicina, una dosis fija de 13.3 mg de clofazimina y una dosis fija de 40.0 mg de rifabutina; e instrucciones de uso.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063046322P | 2020-06-30 | 2020-06-30 | |
| US202063046335P | 2020-06-30 | 2020-06-30 | |
| PCT/IB2021/000451 WO2022003421A2 (en) | 2020-06-30 | 2021-06-30 | Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000165A true MX2023000165A (es) | 2023-02-22 |
Family
ID=79032054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000165A MX2023000165A (es) | 2020-06-30 | 2021-06-30 | Productos de combinacion de dosis fijas de tres antibioticos, regimen de dosificacion, metodos y kits para tratar infecciones micobacterianas pulmonares no tuberculosas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11590154B2 (es) |
| EP (1) | EP4171546A4 (es) |
| JP (1) | JP2023533472A (es) |
| KR (1) | KR20230028502A (es) |
| CN (1) | CN115768420A (es) |
| AU (1) | AU2021298936A1 (es) |
| BR (1) | BR112022026615A2 (es) |
| CA (1) | CA3187031A1 (es) |
| IL (1) | IL299287A (es) |
| MX (1) | MX2023000165A (es) |
| WO (1) | WO2022003421A2 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998043667A1 (en) | 1997-04-01 | 1998-10-08 | Borody Thomas J | Methods and compositions for treating inflammatory bowel disease |
| SI2247291T1 (sl) * | 2008-02-08 | 2019-03-29 | Red Hill Biopharma Ltd. | Metode in sestavki za obravnavo kronične vnetne črevesne bolezni |
| TWI573590B (zh) * | 2011-09-20 | 2017-03-11 | 雷希爾生藥有限公司 | 治療自體免疫疾病之組成物及方法 |
| EP3356447A4 (en) * | 2015-10-01 | 2019-06-12 | Memorial Sloan-Kettering Cancer Center | INHIBITORS OF MENACHINONE BIOSYNTHESIS |
| WO2017194734A1 (en) * | 2016-05-13 | 2017-11-16 | Technische Universität München | Means and methods for treating mycobacterial diseases |
-
2021
- 2021-06-30 JP JP2022580214A patent/JP2023533472A/ja active Pending
- 2021-06-30 KR KR1020237002839A patent/KR20230028502A/ko active Search and Examination
- 2021-06-30 WO PCT/IB2021/000451 patent/WO2022003421A2/en unknown
- 2021-06-30 MX MX2023000165A patent/MX2023000165A/es unknown
- 2021-06-30 US US17/364,124 patent/US11590154B2/en active Active
- 2021-06-30 BR BR112022026615A patent/BR112022026615A2/pt unknown
- 2021-06-30 AU AU2021298936A patent/AU2021298936A1/en active Pending
- 2021-06-30 IL IL299287A patent/IL299287A/en unknown
- 2021-06-30 CA CA3187031A patent/CA3187031A1/en active Pending
- 2021-06-30 CN CN202180044988.XA patent/CN115768420A/zh active Pending
- 2021-06-30 EP EP21834321.8A patent/EP4171546A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11590154B2 (en) | 2023-02-28 |
| BR112022026615A2 (pt) | 2023-01-24 |
| US20210401865A1 (en) | 2021-12-30 |
| JP2023533472A (ja) | 2023-08-03 |
| CN115768420A (zh) | 2023-03-07 |
| EP4171546A4 (en) | 2024-03-13 |
| KR20230028502A (ko) | 2023-02-28 |
| CA3187031A1 (en) | 2022-01-06 |
| AU2021298936A1 (en) | 2023-01-19 |
| EP4171546A2 (en) | 2023-05-03 |
| WO2022003421A3 (en) | 2022-03-17 |
| WO2022003421A2 (en) | 2022-01-06 |
| IL299287A (en) | 2023-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jensen et al. | Oral mucosal lesions, microbial changes, and taste disturbances induced by adjuvant chemotherapy in breast cancer patients | |
| Hooper | New uses for new and old quinolones and the challenge of resistance | |
| Herrera et al. | Antimicrobial therapy in periodontitis: the use of systemic antimicrobials against the subgingival biofilm | |
| Ringdahl | Treatment of recurrent vulvovaginal candidiasis | |
| Pines et al. | Antibiotic regimens in moderately ill patients with purulent exacerbations of chronic bronchitis | |
| NZ552047A (en) | Method of treatment of endobronchial infections | |
| EP1243267A3 (en) | Amoxycillin and clavulanate containing pharmaceutical formulation | |
| CO5021201A1 (es) | Metodo de tratar infecciones bacterianas causadas potencial- mente por streptococcus pneumoniae | |
| Blomgren et al. | Fluconazole versus nystatin in the treatment of oral candidosis | |
| Galgiani et al. | Bacteroides fragilis endocarditis, bacteremia and other infections treated with oral or intravenous metronidazole | |
| DINSMOOR et al. | A randomized, double-blind, placebo-controlled trial of oral antibiotic therapy following intravenous antibiotic therapy for postpartum endometritis | |
| Weiss et al. | Acute nonspecific lung abscess: a controlled study comparing orally and parenterally administered penicillin G | |
| Hooper et al. | Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects | |
| MX2023000165A (es) | Productos de combinacion de dosis fijas de tres antibioticos, regimen de dosificacion, metodos y kits para tratar infecciones micobacterianas pulmonares no tuberculosas. | |
| MXPA04012410A (es) | Composiciones, formulaciones y equipo para el tratamiento de enfermedades pulmonares y respiratorias con deshidroepiandrosteronas, esteroides y agentes antimuscarinicos. | |
| AU777508B2 (en) | Methods and kits for treating vulvovaginal candidiasis with miconazole nitrate | |
| US20060210483A1 (en) | Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections | |
| Edelstein et al. | Once‐a‐day therapy for sinusitis: a comparison study of cefixime and amoxicillin | |
| Pankhurst et al. | Prophylactic application of an intra-alveolar socket medicament to reduce postextraction complications in HIV-seropositive patients | |
| JP2021503448A5 (es) | ||
| US20050214364A1 (en) | Products and methods for treating vaginal infections | |
| Smith et al. | Comparison of oral fleroxacin with oral amoxicillin/clavulanate for treatment of skin and soft tissue infections | |
| Sackel et al. | In vitro activity of p-hydroxybenzyl penicillin (penicillin X) and five other penicillins against Neisseria gonorrhoeae: comparisons of strains from patients with uncomplicated infections and from women with pelvic inflammatory disease | |
| Stillerman | Comparison of cephaloglycin and penicillin in streptococcal pharyngitis | |
| US9700574B2 (en) | Use of secnidazole in treatment of dental infections |